Focused Update on Intracranial Atherosclerosis: Introduction, Highlights, and Knowledge Gaps

HomeStrokeVol. 55, No. 2Focused Update on Intracranial Atherosclerosis: Introduction, Highlights, and Knowledge Gaps No AccessReview ArticleRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessReview ArticleRequest AccessFull TextFocused Update on Intracranial Atherosclerosis: Introduction, Highlights, and Knowledge Gaps Brian L. Hoh and Marc I. Chimowitz Brian L. HohBrian L. Hoh https://orcid.org/0000-0002-4997-4469 Department of Neurosurgery, University of Florida (B.L.H.). and Marc I. ChimowitzMarc I. Chimowitz Correspondence to: Marc I. Chimowitz, MBChB, Department of Neurology, Medical University of South Carolina, 96 Jonathan Lucas St, Clinical Science Building MSC 606, Charleston, SC 29425. Email E-mail Address: [email protected] https://orcid.org/0000-0001-5437-9245 Department of Neurology, Medical University of South Carolina (M.I.C.). Originally published22 Jan 2024https://doi.org/10.1161/STROKEAHA.123.045513Stroke. 2024;55:305–310is related toEmergent Large Vessel Occlusion due to Intracranial Stenosis: Identification, Management, Challenges, and Future DirectionsEpidemiology, Pathophysiology, and Imaging of Atherosclerotic Intracranial DiseaseOptimal Medical Management of Atherosclerotic Intracranial StenosisFuture of Endovascular and Surgical Treatments of Atherosclerotic Intracranial StenosisRandomized Secondary Prevention Trials in Participants With Symptomatic Intracranial Atherosclerotic StenosisFootnotesFor Sources of Funding and Disclosures, see page 308.The podcast and transcript are available at https://www.ahajournals.org/str/podcast.Correspondence to: Marc I. Chimowitz, MBChB, Department of Neurology, Medical University of South Carolina, 96 Jonathan Lucas St, Clinical Science Building MSC 606, Charleston, SC 29425. Email mchimow@musc.eduREFERENCES1. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier.Stroke. 2008; 39:2396–2399. doi: 10.1161/STROKEAHA.107.505776LinkGoogle Scholar2. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis.N Engl J Med. 2011; 365:993–1003. doi: 10.1056/NEJMoa1105335CrossrefMedlineGoogle Scholar3. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.Lancet. 2014; 383:333–341. doi: 10.1016/S0140-6736(13)62038-3CrossrefMedlineGoogle Scholar4. Suri MF, Johnston SC. Epidemiology of intracranial stenosis.J Neuroimaging. 2009; 19:11S–16S. doi: 10.1111/j.1552-6569.2009.00415.xCrossrefMedlineGoogle Scholar5. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia.Ann Neurol. 2007; 61:403–410. doi: 10.1002/ana.21073CrossrefMedlineGoogle Scholar6. Dearborn JL, Zhang Y, Qiao Y, Suri MFK, Liu L, Gottesman RF, Rawlings AM, Mosley TH, Alonso A, Knopman DS, et al. Intracranial atherosclerosis and dementia: the atherosclerosis risk in communities (ARIC) study.Neurology. 2017; 88:1556–1563. doi: 10.1212/WNL.0000000000003837CrossrefMedlineGoogle Scholar7. Gutierrez J, Khasiyev F, Liu M, DeRosa JT, Tom SE, Rundek T, Cheung K, Wright CB, Sacco RL, Elkind MSV. Determinants and outcomes of asymptomatic intracranial atherosclerotic stenosis.J Am Coll Cardiol. 2021; 78:562–571. doi: 10.1016/j.jacc.2021.05.041CrossrefMedlineGoogle Scholar8. Matsui R, Nakagawa T, Takayoshi H, Onoda K, Oguro H, Nagai A, Yamaguchi S. A prospective study of asymptomatic intracranial atherosclerotic stenosis in neurologically normal volunteers in a Japanese cohort.Front Neurol. 2016; 7:39. doi: 10.3389/fneur.2016.00039CrossrefMedlineGoogle Scholar9. Hurford R, Wolters FJ, Li L, Lau KK, Küker W, Rothwell PM. Prognosis of asymptomatic intracranial stenosis in patients with transient ischemic attack and minor stroke.JAMA Neurol. 2020; 77:947–954. doi: 10.1001/jamaneurol.2020.1326CrossrefMedlineGoogle Scholar10. Planas-Ballvé A, Crespo AM, Aguilar LM, Hernández-Pérez M, Canento T, Dorado L, Alzamora MT, Torán P, Pera G, Muñoz-Ortiz L, et al. The Barcelona-asymptomatic intracranial atherosclerosis study: subclinical intracranial atherosclerosis as predictor of long-term vascular events.Atherosclerosis. 2019; 282:132–136. doi: 10.1016/j.atherosclerosis.2019.01.022CrossrefGoogle Scholar11. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries.N Engl J Med. 1987; 316:1371–1375. doi: 10.1056/NEJM198705283162204CrossrefMedlineGoogle Scholar12. Kasner SE, Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Benesch CG, et al; Warfarin Aspirin Symptomatic Intracranial Disease Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.Circulation. 2006; 113:555–563. doi: 10.1161/CIRCULATIONAHA.105.578229LinkGoogle Scholar13. Pasterkamp G, Galis ZS, de Kleijn DP. Expansive arterial remodeling: location, location, location.Arterioscler Thromb Vasc Biol. 2004; 24:650–657. doi: 10.1161/01.ATV.0000120376.09047.feLinkGoogle Scholar14. Gutierrez J, Goldman J, Honig LS, Elkind MS, Morgello S, Marshall RS. Determinants of cerebrovascular remodeling: Do large brain arteries accommodate stenosis?Atherosclerosis. 2014; 235:371–379. doi: 10.1016/j.atherosclerosis.2014.05.925CrossrefMedlineGoogle Scholar15. Amin-Hanjani S, Turan TN, Du X, Pandey DK, Rose-Finnell L, Richardson D, Elkind MS, Zipfel GJ, Liebeskind DS, Silver FL, et al; VERiTAS Study Group. Higher stroke risk with lower blood pressure in hemodynamic vertebrobasilar disease: analysis from the VERITAS study.J Stroke Cerebrovasc Dis. 2017; 26:403–410. doi: 10.1016/j.jstrokecerebrovasdis.2016.09.044CrossrefMedlineGoogle Scholar16. de Havenon A, Zaidat OO, Amin-Hanjani S, Nguyen TN, Bangad A, Abbasi M, Anadani M, Almallouhi E, Chatterjee R, Mazighi M, et al. Large vessel occlusion stroke due to intracranial atherosclerotic disease: identification, medical and interventional treatment, and outcomes.Stroke. 2023; 54:1695–1705. doi: 10.1161/STROKEAHA.122.040008LinkGoogle Scholar17. Kang DH, Kim YW, Hwang YH, Park SP, Kim YS, Baik SK. Instant reocclusion following mechanical thrombectomy of in situ thromboocclusion and the role of low-dose intra-arterial tirofiban.Cerebrovasc Dis. 2014; 37:350–355. doi: 10.1159/000362435CrossrefMedlineGoogle Scholar18. Oliveira R, Correia MA, Marto JP, Carvalho Dias M, Mohamed GA, Nguyen TN, Nogueira RG, Aboul-Nour H, Marin H, Bou Chebl A, et al. Reocclusion after successful endovascular treatment in acute ischemic stroke: systematic review and meta-analysis.J Neurointerv Surg. 2023; 15:964–970. doi: 10.1136/jnis-2022-019382CrossrefGoogle Scholar19. Ballout A, Prochilo G, Kaneko N, Li C, Apfel R, Hinman JD, Liebeskind DS. Computational fluid dynamics in intracranial atherosclerotic disease.Stroke Vasc Interv Neurol. 2023; 61:e000792. doi: 10.1227/01.NEU.0000298914.32248.DCCrossrefGoogle Scholar20. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.N Engl J Med. 2005; 352:1305–1316. doi: 10.1056/NEJMoa043033CrossrefMedlineGoogle Scholar21. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.Stroke. 2005; 36:782–786. doi: 10.1161/01.STR.0000157667.06542.b7LinkGoogle Scholar22. Uchiyama S, Sakai N, Toi S, Ezura M, Okada Y, Takagi M, Nagai Y, Matsubara Y, Minematsu K, Suzuki N, et al; CATHARSIS Study Group. Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS).Cerebrovasc Dis Extra. 2015; 5:1–13. doi: 10.1159/000369610CrossrefMedlineGoogle Scholar23. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, Han Z, Tan KS, Ratanakorn D, Chollate P, et al; CLAIR study investigators. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.Lancet Neurol. 2010; 9:489–497. doi: 10.1016/S1474-4422(10)70060-0CrossrefMedlineGoogle Scholar24. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.N Engl J Med. 2013; 369:11–19. doi: 10.1056/NEJMoa1215340CrossrefMedlineGoogle Scholar25. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.N Engl J Med. 2018; 379:215–225. doi: 10.1056/NEJMoa1800410CrossrefMedlineGoogle Scholar26. Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, et al; CSPS.com Trial Investigators. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.Lancet Neurol. 2019; 18:539–548. doi: 10.1016/S1474-4422(19)30148-6CrossrefMedlineGoogle Scholar27. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA.N Engl J Med. 2020; 383:207–217. doi: 10.1056/NEJMoa1916870CrossrefMedlineGoogle Scholar28. Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, Gupta R, Kirshner H, Megerian JT, Lesko J, et al; VISSIT Trial Investigators. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial.JAMA. 2015; 313:1240–1248. doi: 10.1001/jama.2015.1693CrossrefMedlineGoogle Scholar29. EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial.N Engl J Med. 1985; 313:1191–1200. doi: 10.1056/NEJM198511073131904CrossrefMedlineGoogle Scholar30. Miao Z, Jiang L, Wu H, Bao Y, Jiao L, Li S, Wu J, Hua Y, Li Y, Zhu J, et al. Randomized controlled trial of symptomatic middle cerebral artery stenosis: Endovascular versus medical therapy in a Chinese population.Stroke. 2012; 43:3284–3290. doi: 10.1161/STROKEAHA.112.662270LinkGoogle Scholar31. Gao P, Wang T, Wang D, Liebeskind DS, Shi H, Li T, Zhao Z, Cai Y, Wu W, He W, et al; CASSISS Trial Investigators. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the CASSISS randomized clinical trial.JAMA. 2022; 328:534–542. doi: 10.1001/jama.2022.12000CrossrefGoogle Scholar32. Al Kasab S, Hess DC, Chimowitz MI. Rationale for ischemic conditioning to prevent stroke in patients with intracranial arterial stenosis.Brain Circ. 2016; 2:67–71. doi: 10.4103/2394-8108.186260CrossrefGoogle Scholar33. Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, Li G, Ren C, Luo Y, Ling F, et al. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis.Neurology. 2012; 79:1853–1861. doi: 10.1212/WNL.0b013e318271f76aCrossrefMedlineGoogle Scholar34. Meng R, Ding Y, Asmaro K, Brogan D, Meng L, Sui M, Shi J, Duan Y, Sun Z, Yu Y, et al. Ischemic conditioning is safe and effective for octo- and nonagenarians in stroke prevention and treatment.Neurotherapeutics. 2015; 12:667–677. doi: 10.1007/s13311-015-0358-6CrossrefMedlineGoogle Scholar35. Hou C, Lan J, Lin Y, Song H, Wang Y, Zhao W, Li S, Meng R, Hao J, Ding Y, et al; RICA investigators. Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China.Lancet Neurol. 2022; 21:1089–1098. doi: 10.1016/S1474-4422(22)00335-0CrossrefMedlineGoogle Scholar36. Kim BS, Lim JS, Jeong JU, Mun JH, Kim SH. Regression of asymptomatic intracranial arterial stenosis by aggressive medical management with a lipid-lowering agent.J Cerebrovasc Endovasc Neurosurg. 2019; 21:144–151. doi: 10.7461/jcen.2019.21.3.144CrossrefGoogle Scholar37. Miao H, Yang Y, Wang H, Huo L, Wang M, Zhou Y, Hua Y, Ren M, Ren C, Ji X, et al. Intensive lipid-lowering therapy ameliorates asymptomatic intracranial atherosclerosis.Aging Dis. 2019; 10:258–266. doi: 10.14336/AD.2018.0526CrossrefGoogle Scholar38. Chung JW, Cha J, Lee MJ, Yu IW, Park MS, Seo WK, Kim ST, Bang OY. Intensive statin treatment in acute ischaemic stroke patients with intracranial atherosclerosis: A high-resolution magnetic resonance imaging study (STAMINA-MRI study).J Neurol Neurosurg Psychiatry. 2020; 91:204–211. doi: 10.1136/jnnp-2019-320893CrossrefGoogle Scholar39. Zhou P, Lu Z, Gao P, Wang P, Cao Z, Zhang G, Wang S, Feng Y, Wang P. Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up.Clin Neurol Neurosurg. 2014; 120:6–13. doi: 10.1016/j.clineuro.2014.02.001CrossrefGoogle Scholar40. Park JM, Kim BJ, Kwon SU, Hwang YH, Heo SH, Rha JH, Lee J, Park MS, Kim JT, Song HJ, et al. Intensive blood pressure control may not be safe in subacute ischemic stroke by intracranial atherosclerosis: a result of randomized trial.J Hypertens. 2018; 36:1936–1941. doi: 10.1097/HJH.0000000000001784CrossrefMedlineGoogle Scholar41. Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial.Neurology. 2017; 88:379–385. doi: 10.1212/WNL.0000000000003534CrossrefMedlineGoogle Scholar42. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, Catanese L, Keltai K, Aboyans V, Alings M, et al. Stroke outcomes in the COMPASS trial.Circulation. 2019; 139:1134–1145. doi: 10.1161/CIRCULATIONAHA.118.035864LinkGoogle Scholar43. Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, Yu KH, Koo JS, Wong KS, Lee SH, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.Stroke. 2011; 42:2883–2890. doi: 10.1161/STROKEAHA.110.609370LinkGoogle Scholar44. Al Kasab S, Lynn MJ, Turan TN, Derdeyn CP, Fiorella D, Lane BF, Janis LS, Chimowitz MI; SAMMPRIS Investigators. Impact of the new American heart association/American stroke association definition of stroke on the results of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial.J Stroke Cerebrovasc Dis. 2017; 26:108–115. doi: 10.1016/j.jstrokecerebrovasdis.2016.08.038CrossrefGoogle Scholar45. Abdul Rahman L, Turan TN, Cotsonis G, Almallouhi E, Holmstedt CA, Chimowitz MI. Dual antiplatelet therapy beyond 90 days in symptomatic intracranial stenosis in the sammpris trial.J Stroke Cerebrovasc Dis. 2020; 29:105254. doi: 10.1016/j.jstrokecerebrovasdis.2020.105254CrossrefGoogle Scholar46. Stapleton CJ, Chen YF, Shallwani H, Vakharia K, Turan TN, Woo HH, Derdeyn CP, Charbel FT, Siddiqui AH, Amin-Hanjani S. Submaximal angioplasty for symptomatic intracranial atherosclerotic disease: a meta-analysis of peri-procedural and long-term risk.Neurosurgery. 2020; 86:755–762. doi: 10.1093/neuros/nyz337CrossrefGoogle Scholar47. Seyedsaadat SM, Yolcu YU, Neuhaus A, Rizvi A, Alzuabi M, Murad MH, Brinjikji W, Bydon M, Kallmes DF. Submaximal angioplasty in the treatment of patients with symptomatic icad: a systematic review and meta-analysis.J Neurointerv Surg. 2020; 12:380–385. doi: 10.1136/neurintsurg-2019-015451CrossrefGoogle Scholar48. Jia B, Zhang X, Ma N, Mo D, Gao F, Sun X, Song L, Liu L, Deng Y, Xu X, et al; NOVA Trial Investigators. Comparison of drug-eluting stent with bare-metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis: a randomized clinical trial.JAMA Neurol. 2022; 79:176–184. doi: 10.1001/jamaneurol.2021.4804CrossrefGoogle Scholar49. Gonzalez NR, Dusick JR, Connolly M, Bounni F, Martin NA, Van de Wiele B, Liebeskind DS, Saver JL. Encephaloduroarteriosynangiosis for adult intracranial arterial steno-occlusive disease: long-term single-center experience with 107 operations.J Neurosurg. 2015; 123:654–661. doi: 10.3171/2014.10.JNS141426CrossrefMedlineGoogle Scholar50. Gonzalez NR, Jiang H, Lyden P, Song S, Schlick K, Dumitrascu O, Quintero-Consuegra MD, Toscano JF, Liebeskind DS, Restrepo L, et al. Encephaloduroarteriosynangiosis (EDAS) revascularization for symptomatic intracranial atherosclerotic steno-occlusive (ERSIAS) phase-II objective performance criterion trial.Int J Stroke. 2021; 16:701–709. doi: 10.1177/1747493020967256CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesEmergent Large Vessel Occlusion due to Intracranial Stenosis: Identification, Management, Challenges, and Future DirectionsSami Al Kasab, et al. Stroke. 2024;55:355-365Epidemiology, Pathophysiology, and Imaging of Atherosclerotic Intracranial DiseaseLi Hui Chen, et al. Stroke. 2024;55:311-323Optimal Medical Management of Atherosclerotic Intracranial StenosisAshley M. Wabnitz, et al. Stroke. 2024;55:335-343Future of Endovascular and Surgical Treatments of Atherosclerotic Intracranial StenosisTheresa A. Elder, et al. Stroke. 2024;55:344-354Randomized Secondary Prevention Trials in Participants With Symptomatic Intracranial Atherosclerotic StenosisLauren E. Dunn, et al. Stroke. 2024;55:324-334 February 2024Vol 55, Issue 2 Advertisement Stroke Alert February 2024 February 15, 2024 Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.123.045513PMID: 38252758 Originally publishedJanuary 22, 2024 Keywordsantithrombotic agentscerebral revascularizationintracranial atherosclerosisprevalencerandomized clinical trialsrisk factorsstrokePDF download Advertisement SubjectsEpidemiologyImagingRevascularizationRisk FactorsSecondary Prevention